Large Molecule Patents
Prolia And Xgeva is a drug owned by Amgen Inc.. It is protect by 47 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11744950 | AMGEN INC. | Controlled dispense syringe |
Nov, 2039
(14 years from now) | Active |
| US11098079 | AMGEN INC. | Charged depth filtration of antigen-binding proteins |
Jul, 2037
(12 years from now) | Active |
| US11275090 | AMGEN INC. | Quantitation of glycan moiety in recombinant glycoproteins |
Jul, 2037
(12 years from now) | Active |
| US10167492 | AMGEN INC. | Process for manipulating the level of glycan content of a glycoprotein |
Dec, 2035
(10 years from now) | Active |
| US10822630 | AMGEN INC. | Process for manipulating the level of glycan content of a glycoprotein |
Dec, 2035
(10 years from now) | Active |
| US11786866 | AMGEN INC. | Process control systems and methods for use with filters and filtration processes |
Oct, 2035
(10 years from now) | Active |
| US10583397 | AMGEN INC. | Process control systems and methods for use with filters and filtration processes |
Jul, 2035
(10 years from now) | Active |
| US11384378 | AMGEN INC. | Methods for harvesting mammalian cell cultures |
Jun, 2035
(10 years from now) | Active |
| US11427848 | AMGEN INC. | Methods for harvesting mammalian cell cultures |
Jun, 2035
(10 years from now) | Active |
| US11077404 | AMGEN INC. | Process control systems and methods for use with filters and filtration processes |
May, 2035
(10 years from now) | Active |
| US11130980 | AMGEN INC. | Use of monensin to regulate glycosylation of recombinant proteins |
Apr, 2035
(10 years from now) | Active |
| US10106829 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US10227627 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US10655156 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US10907186 | AMGEN INC. | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US10513723 | AMGEN INC. | Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US11254963 | AMGEN INC. | Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins |
Dec, 2034
(9 years from now) | Active |
| US11299760 | AMGEN INC. | Use of monensin to regulate glycosylation of recombinant proteins |
Oct, 2034
(9 years from now) | Active |
| US10421987 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | Active |
| US10894972 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | Active |
| US11434514 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | Active |
| US11946085 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | Active |
| US9481901 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | Active |
| US11319568 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | Active |
| US11459595 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | Active |
| US11952605 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | Active |
| US9328134 | AMGEN INC. | Carbohydrate phosphonate derivatives as modulators of glycosylation |
Feb, 2034
(9 years from now) | Active |
| US11486883 | AMGEN INC. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
Mar, 2033
(8 years from now) | Active |
| US11292829 | AMGEN INC. | Mammalian cell culture |
Jun, 2032
(7 years from now) | Active |
| US11634476 | AMGEN INC. | Mammalian cell culture |
Jun, 2032
(7 years from now) | Active |
| US11685772 | AMGEN INC. | Mammalian cell culture |
Jun, 2032
(7 years from now) | Active |
| US9133493 | AMGEN INC. | Method for culturing mammalian cells to improve recombinant protein production |
Apr, 2032
(7 years from now) | Active |
| US9388447 | AMGEN INC. | Method for culturing mammalian cells to improve recombinant protein production |
Apr, 2032
(7 years from now) | Active |
| US9012178 | AMGEN INC. | Dipeptides to enhance yield and viability from cell cultures |
Aug, 2031
(6 years from now) | Active |
| US9320816 | AMGEN INC. | Methods of treating cell culture media for use in a bioreactor |
Nov, 2030
(5 years from now) | Active |
| US8053236 | AMGEN INC. | Feed media |
Jan, 2030
(5 years from now) | Active |
| US9228168 | AMGEN INC. | Feed media |
Jan, 2030
(5 years from now) | Active |
| US9359435 | AMGEN INC. | Methods for modulating mannose content of recombinant proteins |
May, 2027
(2 years from now) | Active |
| US7662930 | AMGEN INC. | Polishing steps used in multi-step protein purification processes |
Apr, 2027
(2 years from now) | Active |
| US7888101 | AMGEN INC. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
Apr, 2027
(2 years from now) | Active |
| US7928205 | AMGEN INC. | Methods for refolding of recombinant antibodies |
Feb, 2027
(2 years from now) | Active |
| US8247210 | AMGEN INC. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
Dec, 2026
(1 year, 11 months from now) | Active |
| US8460896 | AMGEN INC. | Host cells and culture methods |
Dec, 2026
(1 year, 11 months from now) | Active |
| US8680248 | AMGEN INC. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
Dec, 2026
(1 year, 11 months from now) | Active |
| US7427659 | AMGEN INC. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
Mar, 2025
(2 months from now) | Active |
| US7364736 | AMGEN INC. | Antibodies to OPGL |
Feb, 2025
(2 months from now) | Active |
| US8058418 | AMGEN INC. | Polynucleotides encoding heavy and light chains of antibodies to OPGL |
Nov, 2023
(1 year, 19 days ago) |
Expired |
Prolia And Xgeva's Family Patents
Explore Our Curated Drug Screens
About Prolia And Xgeva
Active Ingredients:
Approval Date:
Dosage:
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG/ML | Injection | Disc | Subcutaneous |
| 120MG/1.7ML (70MG/ML) | Injection | Rx | Subcutaneous |
| 120MG/1.7ML (70MG/ML) | Injection | Rx | Subcutaneous |
| 120MG/1.7ML (70MG/ML) | Injection | Rx | Subcutaneous |
| 60MG/ML | Injection | Disc | Subcutaneous |
| 60MG/ML | Injection | Disc | Subcutaneous |
| 60MG/ML | Injection | Rx | Subcutaneous |
| 60MG/ML | Injection | Rx | Subcutaneous |
| 60MG/ML | Injection | Rx | Subcutaneous |